Plasmacytoma of the mastoid bone: solitary and systemic

Engelsma, R. J. Y.; Bree, Remco de; Janssen, Jeroen; Scheeren, R. A.

doi:10.1258/0022215001905625

Cited by 13 publications

(10 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As noted above, the possibility of a lesion presenting in the absence of a previous MM diagnosis exists, and it is also noteworthy that some cases of SPB are not clearly associated with systemic disease even with years of follow-up (3,20). The findings of the present study suggest that MM is ultimately associated with SPB of the temporal bone in approximately half of cases.…”

Section: Discussionsupporting

confidence: 61%

Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the Literature

Sweeney

Hunter

Rajkumar³

et al. 2017

Otology &Amp; Neurotology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 61%

Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the Literature

Sweeney

Hunter

Rajkumar³

et al. 2017

Otology &Amp; Neurotology

View full text Add to dashboard Cite

show abstract

“…Plasma cell neoplasm is radiosensitive; therefore, local debulking followed by radiotherapy had a good result on it. Once disease becomes multiple myeloma, then prognosis is not as good as plasmacytoma; chemotherapy should be added [13,14] . The potential for malignant systemic progression is higher for solitary plasmocytomas of bone than for extramedullary plasmocytomas [15] .…”

Section: Discussionmentioning

confidence: 99%

Solitary Plasmacytoma of Scalp without Intra Cranial ExtensionA Cytological Rare Case Report

Woike¹

2016

jmscr

View full text Add to dashboard Cite

“…The treatment of CNS plasmacytomas changes according to the extent of the disease, in solitary tumors, local surgical debulking followed by radiotherapy have shown good outcomes but once the disease becomes systemic, chemotherapy is the main treatment [23,24,25]. It has been reported that extramedullary localizations of myeloma originating from the cranial bone usually respond well to new drugs (e.g., thalidomide, bortezomid and lenalidome) compared tointraparenchyma plasmacytomas [26].…”

Section: Discussionmentioning

confidence: 99%

Parietal Plasmacytoma: An Ominous Sign of Disease Recurrence

Duma¹,

Patel²,

Nasereddin³

2015

AJMCR

View full text Add to dashboard Cite

Plasmacytomas located in the central nervous system are rareentities; with no pathognomonic clinical or radiologic features histology is required for a definite diagnosis. We present a case of a dural plasmacytoma as the manifestation of disease recurrence in a patient with systemic multiple myeloma. 51 year old male with history of IgG kappa myeloma, who underwent complete remission after an autologous bone marrow transplant presented to the clinic 10 months post-remission complaining of a "head mass". On physical examination, he was found to have a large soft mass in the parietal area. On MRI the lesion was described as an extra-axial mass, 5.5 cm x5cm diameter, with diffuse enhancement of the dura. Biopsy of the mass revealed anextramedullary plasmacytoma. At that time, his M spike and immunoglobulins levels were unremarkable. Several months after the presentation of the parietal mass, the patient developed recurrence of disease. He underwent a second autologous bone marrow transplant that markedly improved the size of the plasmacytoma. Patient achieved a complete remission after the second transplant. However, 6 months later the dural plasmacytoma increased in size and once again and his myeloma markers remained within normal levels. Unfortunately, recurrence of the multiple myeloma occurred several months later and despite several cycles of chemotherapy, the patient continued to have progression of disease. He then decided for a more conservative treatment and was sent to home hospice. Central nervous system plasmacytomas can present as solitary lesions or as part of systemic multiple myeloma, these tumors tend to have a direct relationship with the activity of the disease and can present as an early sign of recurrence despite normal multiple myeloma markers on peripheral blood. Keywords: dural plasmacytoma, multiple myeloma, solitary plasmacytoma, multiple myeloma recurrenceCite This Article: Narjust Duma MD, Dhruvesh Patel, and Thayer Nasereddin, "Parietal Plasmacytoma: An Ominous Sign of Disease Recurrence." American Journal of Medical Case Reports, vol. 3, no. 6 (2015): 163-166. doi: 10.12691/ajmcr-3-6-4. BackgroundPlasma cell neoplasms can be broadly categorized into multiple myeloma and plasmacytomas. Multiple myeloma, the more common form of plasma cell neoplasms, is composed of abnormal plasma cells that proliferate in the bone marrow. These abnormal cells disrupt normal hematopoiesis, invade adjacent bone and produce paraproteins. Anemia, hypercalcemia, and renal insufficiency are the consequent symptoms of this systemic disease. In contrast to multiple myeloma, plasmacytomas are composed of a mass of neoplastic plasma cells. These masses can be isolated neoplasms with or without the systemic symptoms of multiple myeloma.Plasmacytomas are further subdivided inthree distinct types of plasmacytomas-solitary plasmacytoma of the bone, extramedullary plasmacytoma and multiple plasmacytomas that are either primary or recurrent [1]. Extramedullary plasmacytomas account for 3% of plasma cell neopl...

show abstract

Plasmacytoma of the mastoid bone: solitary and systemic

Cited by 13 publications

References 12 publications

Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the Literature

Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the Literature

Solitary Plasmacytoma of Scalp without Intra Cranial ExtensionA Cytological Rare Case Report

Parietal Plasmacytoma: An Ominous Sign of Disease Recurrence

Contact Info

Product

Resources

About